FDA Grants Orphan Drug Designation for belumosudil for systemic sclerosis

This Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor is currently being studied in an ongoing Phase 2 clinical trial comparing a 200 mg daily and twice daily dose regimen with placebo. It is also being investigated for use in chronic graft-versus-host disease.

Biospace Inc.